Acute Promyelocytic Leukemia

Description

Acute promyelocytic leukemia (APL) is an aggressive form of acute myeloid leukemia (AML; see this term), characterized by arrest of leukocyte differentiation at the promyelocyte stage, due to a specific chromosomal translocation t(15;17) in myeloid cells. APL manifests with easy bruising, hemorrhagic diathesis and fatigue.

Clinical Features

Phenotypes and symptoms related to Acute Promyelocytic Leukemia

  • Leukemia
  • Acute promyelocytic leukemia
  • Abnormal granulocytopoietic cell morphology

Incidence and onset information

— Based on the latest data available ACUTE PROMYELOCYTIC LEUKEMIA have a estimated incidence of 0.11 per 100k worldwide.
No data available about the known clinical features onset.

Alternative names

Acute Promyelocytic Leukemia Is also known as acute myeloid leukemia with t(15;17)(q22;q12);(pml/raralpha) and variants, acute myeloblastic leukemia 3, apml, aml m3, aml with t(15;17)(q22;q12);(pml/raralpha) and variants, leukemia, acute promyelocytic.

Researches and researchers

Doctors, researchs, and experts related to Acute Promyelocytic Leukemia extracted from public data.

Acute Promyelocytic Leukemia Experts map



Current Researchs and researchers

  • LEUVEN — Pr Peter A VANDENBERGHE

    Responsible for diagnostic tests - Investigator of research project

    • Institution/s:
      — Department of Human Genetics, University Hospitals Leuven - Gasthuisberg
    • Research area/topic::

      The role of RAS- and RHO-GTPases, their regulators and mediators in the pathogenesis of myeloid malignancies.


  • DRESDEN — Pr Uwe PLATZBECKER

    Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Investigator of research project

    • Institution/s:
      — Universitätsklinikum Carl Gustav Carus an der TU Dresden
      — Universitätsklinikum Carl Gustav Carus an der TU Dresden
    • Research area/topic::

      NAPOLEON Registry of the German AML Intergroup - National acute promyelocytic leukemia observational study


  • MANNHEIM — Dr Susanne SAUßELE

    Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Investigator of research project - Coordinator of research network

    • Institution/s:
      — III. Medizinische Universitäts-Klinik, Universitätsklinikum Mannheim
      — Universitätsmedizin Mannheim
    • Research area/topic::

      Competence Network 'acute and chronic leukemias'


  • STUTTGART — Pr Jochen GREINER

    Investigator of research project

    • Institution/s:
      — Diakonie-Klinikum Stuttgart
    • Research area/topic::

      AMLSG 18-12: Maintenance therapy with Histamine Dihydrochloride and Interleukin-2 in adult AML patients with measurable minimal residual disease - a Non-interventional Study



Mendelian

Accelerate your rare disease diagnosis with us

Learn more

Acute Promyelocytic Leukemia Recommended genes panels

Panel Name, Specifity and genes Tested/covered
Hereditary Endocrine Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

SDHA, SDHB, SDHC, SDHD, TP53, VHL, CDC73, SDHAF2, TMEM127, MAX, MEN1, PRKAR1A, PTEN, RET
Specificity
8 %
Genes
3 %
Comprehensive Hereditary Cancer Panel.

By Baylor Miraca Genetics Laboratories (United States).

RUNX1, SDHA, SDHB, SDHC, SDHD, BMPR1A, BRCA1, BRCA2, STK11, EPCAM, TP53, VHL, WT1, CBL, SUFU, CDC73, CDH1, CDK4, CDKN1C, CDKN2A , (...)

View the complete list with 39 more genes
Specificity
4 %
Genes
6 %
Inherited Cancer Panel.

By Knight Diagnostic Laboratories - Molecular Diagnostic Center Oregon Health & Science University (United States).

BLM, SDHB, BMPR1A, BRCA1, BRCA2, STK11, EPCAM, TP53, TSC1, TSC2, VHL, XRCC2, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, BRIP1, SDHAF2, TMEM127 , (...)

View the complete list with 28 more genes
Specificity
3 %
Genes
3 %
VistaSeq Hereditary Cancer Panel.

By Molecular Diagnostic Laboratory University of Alberta (Canada).

BMPR1A, BRCA1, BRCA2, STK11, EPCAM, TP53, CDH1, CDK4, CDKN2A, BRIP1, ABRAXAS1, PALB2, APC, SMAD4, MLH1, MSH2, MSH6, MUTYH, NBN, ATM , (...)

View the complete list with 6 more genes
Specificity
4 %
Genes
3 %
Vistaseq Hereditary Cancer Panel Without BRCA.

By Molecular Diagnostic Laboratory University of Alberta (Canada).

BMPR1A, STK11, EPCAM, TP53, CDH1, CDK4, CDKN2A, BRIP1, ABRAXAS1, PALB2, APC, SMAD4, MLH1, MSH2, MSH6, MUTYH, NBN, ATM, PMS2, PRKAR1A , (...)

View the complete list with 4 more genes
Specificity
5 %
Genes
3 %
VistaSeq Endrocrine Cancer Panel.

By Molecular Diagnostic Laboratory University of Alberta (Canada).

SDHB, SDHC, SDHD, TP53, VHL, CDC73, TMEM127, MAX, MEN1, NF1, PRKAR1A, PTEN, RET
Specificity
8 %
Genes
3 %
Hypoparathyroidism Deletion/Duplication Panel.

By Genetic Services Laboratory University of Chicago (United States).

STX16, TBCE, TBX1, CASR, CHD7, FAM111A, CYP24A1, AIRE, GATA3, GCM2, GNA11, GNAS, HADHA, HADHB, PDE4D, PRKAR1A, PTH
Specificity
6 %
Genes
3 %
Hypoparathyroidism sequencing panel.

By Genetic Services Laboratory University of Chicago (United States).

STX16, TBCE, TBX1, CASR, CDH7, FAM111A, CYP24A1, AIRE, GATA3, GCM2, GNA11, GNAS, HADHA, HADHB, PDE4D, PRKAR1A, PTH
Specificity
6 %
Genes
3 %

We have 812 more panels available in our App

Get the app

Sources and references

You can check the following sources for additional information.

OMIM ORPHANET MESH Rare Disease Symptoms Checker

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like SHASHI-PENA SYNDROME; SHAPNS PYCNODYSOSTOSIS LEBER CONGENITAL AMAUROSIS 7; LCA7 MYOCLONIC-ASTASTIC EPILEPSY CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE LEUKODYSTROPHY, HYPOMYELINATING, 9; HLD9

Need help with a diagnosis?

Learn more about how to achieve it with Mendelian


Learn more